Epidemiology and prevention of hepatitis B virus infection

So Young Kwon and Chang Hong Lee

Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea

Hepatitis B virus (HBV) infection has been a major global cause of morbidity and mortality. The recognition of the problem led to a worldwide effort to reduce transmission of HBV through routine infant vaccination. HBV infection is the most common cause of chronic liver diseases and hepatocellular carcinoma in Korea. After hepatitis B vaccine era, seroprevalence of hepatitis B surface antigen is decreasing, particularly in children. Hepatitis B vaccine is remarkably safe and shows high immunogenicity. Universal childhood immunization with three doses of hepatitis B vaccine in the first year of life is a highly effective method for prevention and control of hepatitis B. (Korean J Hepatol 2011;17:87-95)

Keywords: Hepatitis B virus; Epidemiology; Vaccine; Prevention

INTRODUCTION

Hepatitis B is an infectious disease, associated with an estimated 350 million chronically infected patients.1 Perinatal transmission is an important cause of hepatitis B virus (HBV) transmission, account for 35% to 50% of HBV carriers.2 Korea is an endemic area of HBV infection, therefore, hepatitis B is an important public health problem. This review describes an overview of HBV infection, epidemiology, immunization, and prevention.

HEPATITIS B VIRUS

HBV is a 42-nm DNA virus in the family Hepadnaviridae. The virus has a partially double-stranded DNA with core antigen surrounded by a shell containing surface antigen (HBsAg).3 HBV contains numerous antigenic components, including HBsAg, HBeAg, and hepatitis B e antigen (HBeAg). The HBV genome has 3200 nucleotides, and it efficiently uses its genetic information to encode four groups of proteins and their regulatory elements by shifting the reading frames over the same genetic material.4 The immune response to HBsAg provides the immunity against HBV. Antibodies to HBeAg indicate infection, IgM anti-HBe indicates recent infection and usually disappears within six months, while IgG anti-HBe persists for life and indicates past infection. Antibody to HBsAg (anti-HBs) appears after clearance of HBsAg or after immunization. The presence of HBsAg for more than six months is defined as chronic HBV infection.

MODE OF TRANSMISSION

HBV is transmitted parenterally by contaminated blood or other body fluids through blood vessels, skin or mucous membranes. The virus can be detected in all human body fluids, the virus concentration in the fluids is highest in the blood or serous exudates, and it is relatively low in saliva, semen, vaginal fluids.5 Thus, there is almost no risk of transmission in the course of daily life, and the infection...
The main transmission routes include perinatal infection, the skin and mucous membrane infections caused by contaminated blood or body fluids (blood transfusion, use of contaminated syringes, hemodialysis, invasive tests or surgery), and sexual contacts. In Korea, the most important route is perinatal transmission in patients with chronic hepatitis B.

Perinatal infection occurs frequently if the mother with HBV is HBeAg-positive and has a high level of serum HBV-DNA. If infants born to HBsAg-positive mother do not receive perinatal hepatitis B vaccine and immunoglobulin prophylaxis, infection rates in infants born to HBsAg positive and negative mother are 70 to 90% and 10 to 20%, respectively, of which 90% will progress to chronic infection. When given with vaccine and immunoglobulin within 24 hours after birth, 90% of infants show the preventive effect. Although a very small amount of HBV is detected in breast milk, there is no evidence that hepatitis B is transmitted through breast milk.

In injection drug abuser, using the same syringe among injection drug users at the same time is the main transmission route of hepatitis B infection. In addition, tattooing, ear piercing, acupuncture, dialysis, and even using a syringe can be the source of infection.

In adolescents and adults in the countries with low and middle prevalence rates of hepatitis B, sexual contact is the major cause of HBV infection. Recently, as the prevalence of HBV infection is decreasing in young adult age group in Korea, the sexual contact has become the main transmission route.

CLINICAL FEATURES

Hepatitis B shows variable clinical manifestations ranging from asymptomatic HBV carriers to fulminant liver failure, and it becomes chronic, often progresses to chronic hepatitis, cirrhosis, and hepatocellular carcinoma. These clinical manifestations may vary depending on their age at infection, showing symptoms in less than 10% of children under 5 years old, while causing symptoms of the infection in 30 to 50% in adults. The risk of chronic HBV infection varies inversely with age; 80 to 90% of neonatal infections, 30 to 60% of infants, 5% or less of adults. The majority of cases of vertical transmission from mother progresses to chronic carriers.

The incubation period for the onset of acute hepatitis B is 3 to 4 months, showing prodromal symptoms such as fatigue, fever and anorexia, which are similar to other viral hepatitis. Serum-sickness syndromes such as joint pain and rash were observed in about 10% of patients. Jaundice occurs at 1 or 2 weeks after the onset of symptoms, and clinical symptoms are improved in the majority of cases within 3 months. Fulminant hepatitis, accompanied by hepatic encephalopathy is complicated in 0.5% of cases in adult patients. In most cases of acute hepatitis B, HbsAg disappears within 6 months and liver function is recovered. When the virus persists longer than 6 months, it becomes a chronic state. The natural history of chronic hepatitis B is determined by the immune response and viral replication. The initial phase of perinatally acquired infections is characterized by high levels of virus replication with no evidence of active liver disease with normal transaminase levels due to immune tolerance. The second phase of perinatally acquired chronic infection, immune clearance phase, is characterized by high levels of virus replication with active liver disease. Fibrosis of the liver can develop during this phase, which can lead to cirrhosis. During the immune clearance phase, seroconversion of HBeAg and decrease in HBV DNA level may occur, hereafter staying as 'inactive HBV carriers' with low viral load and normal liver function. Some patients show repeated increase in virus levels and necroinflammation, progressing to cirrhosis or liver cancer over a long period of time. The clinical course of hepatitis B is determined by the interaction of viral replication status and host immune response. Otherwise, it can be worsened by the factors such as alcohol and coinfection with other viruses. The risk of progression to decompensated liver disease or the incidence of liver cancer increases with high viral replication status and the risk is higher in patients with cirrhosis than hepatitis. It has been known that the risk of liver cancer is increased further in patients with older age, family history of liver cancer or cirrhosis, alcohol and the coinfection of hepatitis C virus.

EPIDEMIOLOGY

Hepatitis B is the most common and important cause of cirrhosis and hepatocellular carcinoma in Korea, accounting for approximately 70% of the causes.
HBV is infected by parenteral route through blood or body fluids. In the past, blood transfusions were the mainstream infections, but now there are almost no infections due to the introduction of screening tests for HBV in blood donors and vaccinations. In the areas with high prevalence rate of HBV as in Korea, perinatal transmission from mother to child is the major route of infection. In addition, infections through sexual transmission or needle sharing are possible transmission route in adults.

Until the 1980s before the introduction of hepatitis B vaccine in Korea, the prevalence rate of HBV was almost 8% of the general population. Perinatal infection rate and intrafamily infections were very high in the infant and childhood. Hepatitis B vaccination was introduced in Korea since 1985, and immunization for all neonates and the active and passive immunization for newborns of HBsAg positive mothers have been performed since 1991. After vaccine era, the prevalenc of HBV infection in Seoul metropolitan area was markedly reduced to 0.6% in children under 10 years old, to about 1.6% in the teens, and also it was reduced to 3% in the early 20s. However, the prevalenc rate in 20s and over showed 7.6% in men and 3.4% in women, respectively, indicating no significant differences to the prevalence rates in the past. Perinatal infection in HBV carriers was also as high as 54.7% in age 20 and over, while it was reduced to 7.4% in age less than 10. Hepatitis B vaccine has been included in a National Immunization Program, and since 95% of infants are vaccinated, the neonatal hepatitis B prevention in Korea is being implemented effectively. Recently, the HBsAg positive rate for those under school age is very low at less than 1%. Twenty years after the introduction of the vaccine, the prevalence of HBV infection is decreasing in adolescence and young adults as well as in the ages of infants and children. A nationwide sero-epidemiological survey is needed to provide immunization strategies in adult population.

The occurrence of acute hepatitis B also decreased, and in recent years, it became rarely observed in age groups under 20. The phenomenon of the decrease in young patients with acute hepatitis B is similar to other countries such as Taiwan or the United States, and it is consistent with the time for introduction of hepatitis B vaccination. The reduced incidence of acute hepatitis B in youth ultimately implies the reduced incidence of acute hepatitis B infection for the society or country as a whole. On the other hand, the incidence of acute hepatitis B in the age group over 30 years is relatively high compared to the younger age groups, which might be due to many unvaccinated people.

**EFFICACY OF HEPATITIS B VACCINE**

The ultimate goal of hepatitis B vaccination is to reduce the prevalence of chronic hepatitis B carriers, as well as to prevent the occurrence of acute hepatitis B. Vaccination is the most effective method for the decrease in the prevalence of HBV infection.

Hepatitis B vaccines have been evaluated in clinical trials to determine protective level of serum anti-HBs. Persons who respond to HBV vaccine with titers of anti-HBs 10 mIU/mL or greater are protected against acute hepatitis B and chronic infection. Antibody production rate is higher in the younger age at vaccination and lower for those older than 40 years of age. Thus, antibody test after vaccination is not required for healthy people, however, it should be tested after vaccination in hemodialysis patients, HIV positive people, those at occupational risk of infection such as workers in operation rooms and intensive care unit, babies born to HBsAg-positive mothers, and those with family history of HBV carriers. Since the antibody titer is at maximum around on 1 to 3 months after the completion of vaccine series, the tests for anti-HBs are performed at this time.

The antibody response to hepatitis B vaccine is 90% in healthy adults and 95% of infants, children, and adolescents. As for vaccine efficacy, complete protection has been achieved among immunocompetent persons who developed anti-HBs titers of 10 mIU/mL or greater after completion of vaccination. Long-term follow-up studies of newborn vaccination demonstrated that antibodies become negative in 15-50% among the vaccine responders within 5 to 10 years. In adults, antibodies become negative in 7-50% within 5 years, and 30-60% within 10 years. In the cohort study for 20 years after infant vaccination, booster vaccination in cases of waning antibody produced antibody response rate in excess of 80%, and HBV infection did not occur during the period of the cohort. The persistent protection against clinically significant hepatitis B despite of declining antibody titers is an anamnestic immune response after HBV exposure. This indicates that the immune system would be
able to respond rapidly to HBV infection. At present, routine booster doses of hepatitis B vaccine or periodic serologic test to monitor antibody titers for immune-competent persons who have responded to vaccination is not recommended. However, additional vaccinations are required for immunocompromised patients such as patients with chronic renal failure if antibodies become negative in antibody testing every year after vaccination. Persons who have anti-HBs titer after completion of primary vaccine series less than 10 mIU/mL is called ‘vaccine nonresponders’. Several factors has been associated with nonresponse to HBV vaccination. These include inappropriate vaccine storage conditions, vaccination in buttocks, old age, obesity, hemodialysis, chronic liver disease, and state of immunosuppression, and presence of DR3, DR7 DQ2 and absence of A2 alleles. Approximately 5-10% of vaccinated person do not achieve detectable antibody response (nonresponders).

Further vaccination of the nonresponders administered in the deltoid muscle produces adequate antibody response in 15% to 25% of them after one additional dose and in 30% to 50% after three additional doses.

There are several approaches to improve the antibody response to vaccine. Obesity can be a major cause of lowering the rate of antibody production by the vaccine, recently it has been reported that antibody titers were raised by using long needles. The research for developing new vaccines to improve immunity of the vaccine also has been actively conducted. The vaccines including the Pre-S antigen produced by recombinant DNA methods using CHO cells, or Fendrix containing MPL (3-O-desacyl-4-monophosphoryl lipid A) as an additive to conventional vaccine components can increase the reaction of antibody generation by the vaccine and continue the immune response. In addition, the method to reduce the number of vaccinations to two times in order to increase vaccination rates and compliance of vaccination, various forms of combination vaccines containing HBV components have been developed and currently the combination vaccines with HAV, DTP or Hib have been used. Hepatitis B vaccine has no significant increase in adverse reactions and no interference in antibody response of other immunizations such as DPT, polio, measles, Hib, or hepatitis A. In addition, even when vaccinated with other types of hepatitis B vaccination after a hepatitis B vaccines, there is no difference in vaccine effectiveness. In recent years, the vaccination methods through skin or mucous membranes other than traditional intramuscular injection have been introduced by developing new antigen delivery systems.

Hepatitis B vaccination decreases HBV infection and ultimately reduce the incidence of chronic liver disease or liver cancer. It was reported that incidence of hepatocellular carcinoma in children decreased more than 50% after universal infant and childhood vaccination. In Korea, neonatal vaccination has been conducted and HBsAg positive rate in young adults have recently been greatly reduced, showing only about 3% of HBV infection rate, and it has been decreased less than 1% in children. The incidence of acute hepatitis B has been also reduced, therefore, the incidence of chronic liver diseases or hepatocellular carcinoma by HBV infection could be expected to decrease in the future.

**PREVENTION**

Preventive measures of HBV infection include the avoidance of high-risk behaviors, the prevention of exposure to blood and body fluids, the screening of women in pregnancy for HBV, active immunization or passive immunization before or after exposure. There are active immunization method using vaccines and passive immunization with HBIG.

**Active immunization**

**Types of vaccines**

Plasma vaccines isolated from HBV carriers have been used since 1980s. The plasma vaccines were developed in the early days of vaccines in Korea, and plasma vaccines was used from 1983. Plasma vaccines produce good immunogeneity and they are effective and safe. However, they are rarely used in recent years due to the shortage of plasma of HBsAg carriers, the concerns for the safety of blood product, and the development of recombinant DNA technology. Recombinant DNA vaccines are produced by introducing HBsAg into yeast or mammalian cells (CHO; Chinese Hamster Ovary cell). Antibody conversion rates and geometric means of the generated antibody titers by recombinant vaccines are similar to the plasma vaccines.

Combination vaccines containing a hepatitis B vaccine component are developed. These include DTP-HepB vaccine, DTP-Hib-HepB vaccine, DTP-Hib-inactivated poliovirus vaccine-HepB vaccine, Hib-HepB vaccine, and hepatitis A-HepB vaccine.
Vaccine dose and method

Hepatitis B vaccine includes 20 μg of surface antigen for adults, and 10 μg for children. The vaccine should be given by intramuscular injection in anterolateral aspect of thigh of infants and children less than 2 years of age, and in the deltoid muscle of older children, adolescents, and adults. Injection in the buttocks is not recommended because of the possibility of subcutaneous inoculation into deep fat tissue, which is associated with decreased protective antibody levels. There is no interference effect of simultaneous vaccination with any other vaccines, and in this case, injection site should be in other parts or at least 1.5 cm apart from the hepatitis B vaccine inoculation site.

Hepatitis B vaccine is generally administered in three doses, with the second dose given one month after the first dose and the third dose given six months after the first dose. Vaccines from the other manufacturers can be used interchangeably. If the series is interrupted after the first dose, the second dose should be given as soon as possible and the second and third doses should be separated by an interval of at least 2 months. If the third dose is delayed, it should be given as soon as possible. It is not necessary to restart the vaccine series when there has been a prolonged interval between the doses.

Vaccination shall be given at 0, 1, and 6-month intervals. A second vaccination shall be given at one month after the first vaccination, and in case of missing the vaccination schedule, without having to start again, it shall be given right away, and a third vaccination shall be given at the interval of two months or more after second vaccination.

Storage and safety of vaccines

Most hepatitis B vaccines should be kept in 2-8°C storage temperatures, and the efficacy is maintained at least 4 years. Vaccine efficacy is maintained at room temperature and can be stored for up to one year. Vaccine should not be frozen because the freezing causes the HbsAg protein to dissociate from the alum adjuvant and lose immunogenicity.

Serologic testing

Serologic testing is not indicated before routine vaccination of infants or children. Screening test in adults is considered in the endemic area of HBV infection or in the groups with a high risk of HBV infection. Serologic test following vaccination in healthy adults is not recommended. However, antibody tests should be considered in health care workers who are at the high risk of infection or in the cases of hemodialysis patients, HIV-infected patients, and spouses of hepatitis B patients. Post-vaccination testing should be performed 1-2 months after completion of the vaccine series.

Vaccine non-responder

Anti-HBs response less than 10 mIU/mL after completion of the first vaccine series is called "nonresponders". Re-vaccination is recommended in the nonresponders. Administration of a single dose of vaccine, followed by measurement of anti-HBs antibody response 1-3 months later to differentiate anamnestic response. For persons who are seronegative after the booster dose, a second vaccine series of two additional doses, which result in seroconversion in 50 to 60% of recipients. Generally, additional vaccination is not recommended to the complete nonresponders who do not achieve the appropriate antibody level even after a total of 6 times of vaccinations. HBIG should be administered when they are exposed to HBV.

Adverse reactions

Hepatitis B vaccine is safe and mild side effects appear within 24 hours, showing fever in 1-6%, injection site pain in 3-29%, redness and mild swelling in 3%, and headache in 3%. Arthritis, multiple sclerosis, diabetes, Guillain-Barre syndromes have no direction association to the hepatitis B vaccination. Hypersensitivity to vaccine components, such as yeast, can cause anaphylaxis.

Indications

Comprehensive HBV immunization strategies prevent chronic HBV infection acquired in all age groups. In the past, vaccination to all newborns was performed mainly in the hepatitis B prevalent areas, but since 1997, hepatitis B

| Table 1. Groups of high risk for hepatitis B virus infection |
|-------------------------------------------------------------|
| Homosexually active men                                      |
| Persons at high risk of sexually transmitted HBV infection   |
| Injection drug user                                          |
| Household members and sexual partner of HBV carriers         |
| Clients and staffs in mental health institutions             |
| Patients of hemodialysis units                               |
| Extended travel to areas of high endemicity                  |
| Patients who receive clotting factor concentrates             |
| Persons at occupational risk of HBV infection                |
vaccinations to newborns are being performed worldwide regardless of the prevalence of hepatitis B. Currently, vaccinations to all newborns are being performed and even in adults, catch-up vaccination is recommended in case of unvaccinated person without anti-HBs. It should be particularly recommended to high-risk groups of hepatitis B (Table 1).

### Contraindications

The vaccination is contraindicated in those who have a history of hypersensitivity to vaccine components or who have experienced severe side effects after the hepatitis B vaccination previously. There is limited data on the safety of hepatitis B vaccine for pregnant woman, however, there is no apparent adverse effect to fetus. Therefore, pregnancy or breast feeding are not a contraindication to vaccination. The vaccine can be given to immunocompromised patients, but the antibody response to the vaccination is lower than in healthy people.

### Passive immunization

Hepatitis B vaccination not only prevents hepatitis B but also can attenuate the severity of illness or inhibit the progress toward chronic phase even if they have already been infected and in the incubation period during vaccination. HBIG is recommended for postexposure prophylaxis in the setting of perinatal exposure, percutaneous or mucous membrane exposure to HBV, and sexual exposure to an HBV carrier. It is also used to reduce the risk of recurrent HBV infection after liver transplantation. HBIG is prepared from human plasma of those who contain a high titer of anti-HBs. HBIG is effective in preventing clinical hepatitis B or chronic infection, if used shortly after exposure to HBV.

One of the major uses of HBIG is as an immunoprophylaxis in preventing perinatal HBV transmission. It has been reported that immunoprophylaxis with both HBIG and hepatitis B vaccine could increase the efficacy of preventing perinatal HBV transmission to 85% to 95% and provide long-term protection. HBIG in indicated for postexposure prophylaxis after needle stick injury or percutaneous exposure. In cases of the percutaneous and mucosal exposure to blood or body fluids, such as HBsAg-positive needle stick, the prophylactic procedures vary depending on the vaccination status of the exposed person and the status of antibody. The persons who have anti-HBs after vaccination do not need the vaccine or HBIG. In unvaccinated cases, HBIG 0.06 mL/kg, up to 5 mL is given by intramuscular injection. and the first dose of vaccine should be given within 24 hours after exposure (Table 2). In nonresponders, restart the vaccination after the injection of HBIG immediately. In nonresponders who did not complete re-vaccination after the primary vaccination, it is better to start again after 1 time of HBIG injection. In nonresponders even after 3 times of re-vaccination, it is preferred to perform 2 times of HBIG injection.

### Table 2. Recommendations for postexposure immunoprophylaxis following exposure to hepatitis B virus

| Status of exposed person | Status of source | HBsAg positive | HBsAg negative | Unknown |
|-------------------------|-----------------|----------------|----------------|---------|
| Unvaccinated            |                 | HBIG (1 dose)  | HBV vaccination| HBV vaccination |
| Vaccinated              |                 | HBIG (1 dose)  | HBV vaccination| HBV vaccination |
| Responders *            |                 | No treatment   | No treatment   | No treatment |
| Nonresponders           |                 | HBIG (1 dose)  | HBV vaccination| HBV revaccination (3 doses) |
| Response unknown        |                 | Test anti-HBs  | No treatment   | Test anti-HBs |
|                         |                 | - if positive, no treatment | - if positive, no treatment |
|                         |                 | - if negative, HBIG (1 dose) and HBV vaccination (3 doses) | - if negative, HBIG (1 dose) and HBV revaccination (3 doses) |

*Responders is a person with anti-HBs titer 10 mIU/mL or greater after completion of primary vaccine series. HBIG, hepatitis B immune globulin.
HBV is mainly transmitted through perinatal infection, sexual contact, blood, and contaminated needles from drug abusers. It can be transmitted through the direct contacts or skin wounds between patients and surgeons or dentists, or indirectly through hemodialysis, razors, toothbrushes, and acupuncture therapy. After exposure to HBV contaminated blood or body fluids, HBV contaminated blood should be removed and disinfect the contaminated instruments. In addition, education on the transmission routes to the public and the medical workers are needed for the prevention of HBV infection.

CONCLUSIONS

Hepatitis B immunization has made a hepatitis B a vaccine preventable infectious disease. The hepatitis B vaccine has been associated with decrease in the incidence of HBV infection, and ultimately reduced chronic liver diseases and hepatocellular carcinoma related to HBV infection. Universal vaccination program of infants and children has been successfully control the HBV infection in endemic areas including Korea. We also should pay attention to the prevention of perinatal transmission and HBV infection in unvaccinated adults.

REFERENCES

1. Beasley RP, Hwang LY. Hepatocellular carcinoma and hepatitis B virus. Semin Liver Dis 1984;4:113-121.
2. Stevens CE, Beasley RP, Tsui J, Lee WC. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med 1975;292:771-774.
3. Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev 2000;64:51-68.
4. Chisari FV, Ferrari C, Mondelli MU. Hepatitis B virus structure and biology. Microb Pathog 1989;6:311-325.
5. Margolis HS, Alter MJ, Hadler SC. Viral hepatitis. In: Evans AS, Kaslow RA, eds. Viral Infections of Humans: Epidemiology and Control. 4th ed. New York: Plenum Publishing Corporation, 1997:363-418.
6. Hwang SH, Kim JH, Kang JH, Hur JK, Lee KL, Oh JH, et al. Follow-up of children with chronic hepatitis B virus infection. Korean J Pediatr Infect Dis 2004;11:73-80.
7. Okada K, Kamiyama I, Inomata M, Imai M, Miyakawa Y. e antigen and anti-e in the serum of asymptomatic carrier mothers as indicators of positive and negative transmission of hepatitis B virus to their infants. N Engl J Med 1976;294:746-749.
8. Beasley RP, Trepo C, Stevens CE, Szmuness W. The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol 1977;105:94-98.
9. Beasley RP, Hwang LY, Lee GC, Lan CC, Roan CH, Huang FY, et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet 1983;2:1099-1102.
10. Hutin Y, Stilwell B, Hauri AM, Margolis H. Transmission of blood-borne pathogens through unsafe infections and proposed approach for the safe infection global network. In: Margolis HS, Alter MJ, Liang TJ, Dienstag JL, eds. Viral Hepatitis and Liver Disease: Proceedings of the 10th International Symposium on Viral Hepatitis and Liver Disease. London: International Medical Press, 2002:219-227.
11. Goldstein ST, Alter MJ, Williams JT, Moyer LA, Judson FN, Mottram K, et al. Incidence and risk factors for acute hepatitis B in the United States, 1982-1998: implications for vaccination programs. J Infect Dis 2002;185:713-719.
12. Alter MJ, Margolis HS. The emergence of hepatitis B as a sexually transmitted disease. Med Clin North Am 1990;74:1529-1541.
13. Wright TL, Lau JY. Clinical aspects of hepatitis B virus infection. Lancet 1993;342:1340-1344.
14. McMahon BJ, Alward WL, Hall DB, Heyward WL, Bender TR, Francis DP, et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis 1985;151:590-603.
15. Hyams KC. Risks of chronicity following acute hepatitis B virus infection: a review. Clin Infect Dis 1995;20:992-1000.
16. Dienstag JL. Immunopathogenesis of the extrapathogenic manifestations of hepatitis B virus infection. Springer Semin Immunopathol 1981;3:461-472.
17. Hoofnagle JH, Carithers RL Jr, Shapiro C, Ascher N. Fulminant hepatic failure: summary of a workshop. Hepatology 1995;21:240-252.
18. Lok AS, Lai CL. A longitudinal follow-up of asymptomatic hepatitis B surface antigen-positive Chinese children. Hepatology 1988;8:130:113-1133.
19. Liaw YF, Chu CM, Su JI, Huang MJ, Lin DY, Chang-Chien CS. Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis. Gastroenterology 1983;84:216-219.
20. Alward WL, McMahon BJ, Hall DB, Heyward WL, Francis DP, Bender TR. The long-term serological course of asymptomatic hepatitis B virus carriers and the development of primary hepatocellular carcinoma. J Infect Dis 1985;151:604-609.
21. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-1531.
22. McMahon BJ, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med 2001;135:759-768.
23. Shin HS, Han KH, Park SJ, Ahn SK, Chon CY, Moon YM, et al. The prevalence of hepatitis virus infection and clinical characteristics in patients with hepatocellular carcinoma. Korean J Med 1994;46:467-476.
24. Beasley RP, Hwang LY, Stevens CE, Lin CC, Hsieh FJ, Wang KY, et al. Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: final report of a randomized double-blind, placebo-controlled trial. Hepatology 1983;3:135-141.
30. Korea Centers for Disease Control and Prevention (CDC); 2006 Serosurvey of measles, mumps and hepatitis B. CDC web site (online), <http://www.cdc.go.kr/> Cheongwon: Korea Centers for Disease Control and Prevention, 2007:3-35.
31. Yim HI, Chang YI, Byun KS, Suh YS, Kim JH, Kim JY, et al. The changing patterns of acute hepatitis B infection in Korea in the early 2000s. Korean J Med 2005;69:601-607.
32. Patrick DM, Bigham M, Ng H, White R, Tweed A, Skowronski DM. Elimination of acute hepatitis B among adolescents after one decade of an immunization program targeting Grade 6 students. Pediatr Infect Dis J 2003;22:874-877.
33. Wu JS, Hwang LJ, Goodman KJ, Beasley RP. Hepatitis B vaccination in high-risk infants: 10-year follow-up. J Infect Dis 1999;179:1319-1325.
34. Hessel L, West DJ. Antibody responses to recombinant hepatitis B vaccines. Vaccine 2002;20:2164-2165.
35. Szmuness W, Stevens CE, Harley EJ, Zang EA, Oleszko WR, William DC, et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med 1980;303:833-841.
36. Huang LM, Chiang BL, Lee CY, Lee PI, Chi WK, Chang MH. Long-term response to hepatitis B vaccination and response to booster in children born to mothers with hepatitis B e antigen. Hepatology 1999;29:954-959.
37. Wainwright RB, Bulkow LR, Parkinson AJ, Zanis C, McMahon BJ. Protection provided by hepatitis B vaccine in a Yupik Eskimo population-results of a 10-year study. J Infect Dis 1997;175:674-677.
38. Mintai Z, Kezhou L, Lieming D, Smego RA Jr. Duration and efficacy of immune response to hepatitis B vaccine in high-risk Chinese adolescents. Clin Infect Dis 1993;16:165-167.
39. Poovorawan Y, Chongsrisawat V, Theamboonlers A, Kouch HL, Leyssen M, Jacquet JM. Persistence of antibodies and immune memory to hepatitis B vaccine in high-risk Chinese adolescents. Clin Infect Dis 1993;16:165-167.
40. West DJ, Calandra GB. Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine 1996;14:1019-1027.
41. Averhoff F, Mahoney F, Coleman P, Schatz G, Hurwitz E, Margolis H. Immunogenicity of hepatitis B Vaccines. Implications for persons at occupational risk of hepatitis B virus infection. Am J Prev Med 1998;15:1-8.
42. Peces R, de la Torre M, Alcázar R, Urra JM. Prospective analysis of the factors influencing the antibody response to hepatitis B vaccine in hemodialysis patients. Am J Kidney Dis 1997;29:239-245.
43. Hadler SC, Margolis HS. Hepatitis B immunization: vaccine types, efficacy, and indications for immunization. Curr Clin Top Infect Dis 1992;12:282-308.
44. Poland GA. Hepatitis B immunization in health care workers. Dealing with vaccine nonresponse. Am J Prev Med 1998;15:73-77.
45. Middleman AB, Anding R, Tung C. Effect of needle length when immunizing obese adolescents with hepatitis B vaccine. Pediatrics 2010;125:e508-e512.
46. Sanjay G, Shi L. A review of multiple approaches towards an improved hepatitis B vaccine. Expert Opin Ther Pat 2009;19:59-72.
47. Diez-Delgado I, Dal-Ré R, Llorente M, González A, López J. Hepatitis B component does not interfere with the immune response to diphtheria, tetanus and whole-cell Bordetella pertussis components of a quadrivalent (DTPw-HB) vaccine: a controlled trial in healthy infants. Vaccine 1997;15:1418-1422.
48. Bruguera M, Bayas JM, Villela A, Tural C, González A, Vidal J, et al. Immunogenicity and reactivity of a combined hepatitis A and B vaccine in young adults. Vaccine 1996;14:1407-1411.
49. King GE, Hadler SC. Simultaneous administration of childhood vaccines: an important public health policy that is safe and efficacious. Pediatr Infect Dis J 1999;13:394-407.
50. Atkinson WL, Pickering LK, Schwartz B, Weniger BG, Iskander JK, Watson JC; Centers for Disease Control and Prevention. General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAPF). MMWR Recommm Rep 2002;51:1-35.
51. Lebre F, Borchard G, de Lima MC, Borges O. Progress towards a needle-free hepatitis B vaccine. Pharm Res 2011;28:986-1012.
52. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997;336:1855-1859.
53. Kim CY. Prevention of viral hepatitis, type B, by vaccination with purified hepatitis B surface antigen. J Korean Med Assoc 1979;22:1013-1025.
54. Robert D, Sitrin D, Warnpler E, Ellis RW. Survey of licensed hepatitis B vaccines and their production processes. In: Ellis RW, ed. Hepatitis B Vaccines in Clinical Practice. NewYork: Marcel Dekker, 1993:83-101.
55. Shaw FE Jr, Guess HA, Roets JM, Mohr FE, Coleman PJ, Mandel EJ, et al. Effect of anatomic injection site, age and smoking on the immune response to hepatitis B vaccination. Vaccine 1989;7:425-430.
56. Duval B, Beecuninck G. Seroprotection rates after late doses of hepatitis B vaccine. Pediatrics 2002;109:350-351.
57. Mangione R, Strozzi F, Tosti M, Fragapani P, Mele A. Delayed third hepatitis B vaccine dose and immune response. Lancet 1995;345:1111-1112.
58. Van Damme P, Crumme M, Safary M, Vandepapelière P, Meheus A. Heat stability of a recombinant DNA hepatitis B vaccine. Vaccine 1992;10:366-367.
59. André FE. Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine. Am J Med 1989;87:145-205.
60. McMahon BJ, Helmink C, Wainwright RB, Bulkow L, Trimble BA, Wainwright K. Frequency of adverse reactions to hepatitis B vaccine in 43,618 persons. Am J Med 1992;92:254-256.
61. Centers for Disease Control and Prevention. Update: vaccine side effects, adverse reactions, contraindications, and precautions. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommm Rep 1996;45:1-35.
62. Lear JT, English JS. Anaphylaxis after hepatitis B vaccination. Lancet 1995;345:1249.
63. Kwon SY. Catch-up vaccination in adult, vaccination for adult. In: The Korean Society of Infectious Disease, ed. Infectious Disease. Seoul: Koonja Publishing, 2007:54-65.
64. Levy M, Koren G. Hepatitis B vaccine in pregnancy: maternal and fetal safety. Am J Perinatol 1991;8:227-232.
65. Bruguera M, Cremades M, Salinas R, Costa J, Grau M, Sans J. Impaired response to recombinant hepatitis B vaccine in HIV-infected persons. J
70. Terrault NA, Zhou S, Combs C, Hahn JA, Lake JR, Roberts JP, et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996;24:1327-1333.

71. Seeff LB, Zimmerman HJ, Wright EC, Finkelstein JD, Garcia-Pont P, Greenlee HB, et al. A randomized, double blind controlled trial of the efficacy of immune serum globulin for the prevention of post-transfusion hepatitis. A Veterans Administration cooperative study. Gastroenterology 1977;72:111-121.

72. Xu ZY, Liu CB, Francis DP, Purcell RH, Gun ZL, Duan SC, et al. Prevention of perinatal acquisition of hepatitis B virus carriage using vaccine: preliminary report of a randomized, double-blind placebo-controlled and comparative trial. Pediatrics 1985;76:713-718.

73. Stevens CE, Toy PT, Tong MJ, Taylor PE, Vyas GN, Nair PV, et al. Perinatal hepatitis B virus transmission in the United States. Prevention by passive-active immunization. JAMA 1985;253:1740-1745.